AbbVie annual capital expenditures (capex)
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Capital Expenditures (CapEx) Growth & History (ABBV)
AbbVie's capital expenditures (capex) was $1.21B for fiscal 2025.
View full AbbVie company overviewAbbVie annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.21B | $240.0M | +24.64% |
| 2024 | 2024-12-31 | $974.0M | $197.0M | +25.35% |
| 2023 | 2023-12-31 | $777.0M | $82.0M | +11.80% |
| 2022 | 2022-12-31 | $695.0M | −$92.0M | −11.69% |
| 2021 | 2021-12-31 | $787.0M | −$11.0M | −1.38% |
| 2020 | 2020-12-31 | $798.0M | $246.0M | +44.57% |
| 2019 | 2019-12-31 | $552.0M | −$86.0M | −13.48% |
| 2018 | 2018-12-31 | $638.0M | $109.0M | +20.60% |
| 2017 | 2017-12-31 | $529.0M | $50.0M | +10.44% |
| 2016 | 2016-12-31 | $479.0M | −$53.0M | −9.96% |
| 2015 | 2015-12-31 | $532.0M | −$80.0M | −13.07% |
| 2014 | 2014-12-31 | $612.0M | $121.0M | +24.64% |
| 2013 | 2013-12-31 | $491.0M | $158.0M | +47.45% |
| 2012 | 2012-12-31 | $333.0M | −$23.0M | −6.46% |
| 2011 | 2011-12-31 | $356.0M | — | — |
AbbVie quarterly capital expenditures (capex)
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $322.0M | $53.0M | +19.70% |
| Q1 2026 | 2026-03-31 | $265.0M | $30.0M | +12.77% |
| Q4 2025 | 2025-12-31 | $329.0M | $38.0M | +13.06% |
| Q3 2025 | 2025-09-30 | $381.0M | $132.0M | +53.01% |
| Q2 2025 | 2025-06-30 | $269.0M | $28.0M | +11.62% |
| Q1 2025 | 2025-03-31 | $235.0M | $42.0M | +21.76% |
| Q4 2024 | 2024-12-31 | $291.0M | — | — |
| Q3 2024 | 2024-09-30 | $249.0M | $30.0M | +13.70% |
| Q2 2024 | 2024-06-30 | $241.0M | $63.0M | +35.39% |
| Q1 2024 | 2024-03-31 | $193.0M | $18.0M | +10.29% |
| Q3 2023 · Sep 30 | 2023-09-30 | $219.0M | $42.0M | +23.73% |
| Q2 2023 · Jun 30 | 2023-06-30 | $178.0M | $35.0M | +24.48% |
| Q1 2023 · Mar 31 | 2023-03-31 | $175.0M | $13.0M | +8.02% |
| Q3 2022 · Sep 30 | 2022-09-30 | $177.0M | −$40.0M | −18.43% |
| Q2 2022 · Jun 30 | 2022-06-30 | $143.0M | −$52.0M | −26.67% |
| Q1 2022 · Mar 31 | 2022-03-31 | $162.0M | −$26.0M | −13.83% |
| Q3 2021 · Sep 30 | 2021-09-30 | $217.0M | $0 | 0.00% |
| Q2 2021 · Jun 30 | 2021-06-30 | $195.0M | $18.0M | +10.17% |
| Q1 2021 · Mar 31 | 2021-03-31 | $188.0M | $63.0M | +50.40% |
| Q3 2020 · Sep 30 | 2020-09-30 | $217.0M | $63.0M | +40.91% |
| Q2 2020 · Jun 30 | 2020-06-30 | $177.0M | $49.0M | +38.28% |
| Q1 2020 · Mar 31 | 2020-03-31 | $125.0M | $18.0M | +16.82% |
| Q3 2019 · Sep 30 | 2019-09-30 | $154.0M | −$128.0M | −45.39% |
| Q2 2019 · Jun 30 | 2019-06-30 | $128.0M | $14.0M | +12.28% |
| Q1 2019 · Mar 31 | 2019-03-31 | $107.0M | −$12.0M | −10.08% |
| Q3 2018 · Sep 30 | 2018-09-30 | $282.0M | $156.0M | +123.81% |
| Q2 2018 · Jun 30 | 2018-06-30 | $114.0M | −$12.0M | −9.52% |
| Q1 2018 · Mar 31 | 2018-03-31 | $119.0M | $24.0M | +25.26% |
| Q3 2017 · Sep 30 | 2017-09-30 | $126.0M | $13.0M | +11.50% |
| Q2 2017 · Jun 30 | 2017-06-30 | $126.0M | −$5.0M | −3.82% |
| Q1 2017 · Mar 31 | 2017-03-31 | $95.0M | −$26.0M | −21.49% |
| Q3 2016 · Sep 30 | 2016-09-30 | $113.0M | −$14.0M | −11.02% |
| Q2 2016 · Jun 30 | 2016-06-30 | $131.0M | $16.0M | +13.91% |
| Q1 2016 · Mar 31 | 2016-03-31 | $121.0M | −$24.0M | −16.55% |
| Q3 2015 · Sep 30 | 2015-09-30 | $127.0M | −$53.0M | −29.44% |
| Q2 2015 · Jun 30 | 2015-06-30 | $115.0M | −$27.0M | −19.01% |
| Q1 2015 · Mar 31 | 2015-03-31 | $145.0M | $8.0M | +5.84% |
| Q4 2014 | 2014-12-31 | $153.0M | $2.0M | +1.32% |
| Q3 2014 | 2014-09-30 | $180.0M | $47.0M | +35.34% |
| Q2 2014 | 2014-06-30 | $142.0M | $23.0M | +19.33% |
| Q1 2014 | 2014-03-31 | $137.0M | $49.0M | +55.68% |
| Q4 2013 | 2013-12-31 | $151.0M | $56.0M | +58.95% |
| Q3 2013 | 2013-09-30 | $133.0M | $115.0M | +638.89% |
| Q2 2013 | 2013-06-30 | $119.0M | $25.0M | +26.60% |
| Q1 2013 | 2013-03-31 | $88.0M | −$74.0M | −45.68% |
| Q4 2012 | 2012-12-31 | $95.0M | — | — |
| Q3 2012 | 2012-09-30 | $18.0M | — | — |
| Q2 2012 | 2012-06-30 | $94.0M | — | — |
| Q1 2012 | 2012-03-31 | $162.0M | — | — |
AbbVie capital expenditures (capex) trends
Over the last five fiscal years, AbbVie's capital expenditures (capex) increased from $798.0M to $1.21B, a change of $416.0M. The latest reported quarter, Q2 2026, shows $322.0M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...